

GW/TMH:glh 02/03/06 480776 1-001-01/0
PATENTAttorney Reference Number 6395-64908-01
Application Number 09/826,115

536/29.72

424/218.1

COTM 21/04

AGIK 37/12

ALLOWED CLAIMS
LISTING OF CLAIMS

1. (Previously presented) An isolated nucleic acid comprising a transcriptional unit encoding an engineered Japanese Encephalitis Virus (JEV) signal sequence, which engineered JEV signal sequence comprises SEQ ID NO:14, and an immunogenic flavivirus antigen of a flavivirus other than JEV, wherein the transcriptional unit directs the synthesis of the immunogenic flavivirus antigen.

2. CANCELLED.

2 ~~3~~. (Previously presented) The nucleic acid of claim 1, wherein the immunogenic flavivirus antigen is of a flavivirus selected from the group consisting of yellow fever virus, dengue serotype 1 virus, dengue serotype 2 virus, dengue serotype 3 virus, dengue serotype 4 virus, Powassan virus and West Nile virus.

3 ~~4~~. (Previously presented) The nucleic acid of claim 1, wherein the transcriptional unit encodes the engineered JEV signal sequence and an M protein and an E protein of West Nile virus.

4 ~~5~~. (Previously presented) The nucleic acid of claim 1, wherein the transcriptional unit encodes the engineered JEV signal sequence and an M protein and an E protein of yellow fever virus.

5 ~~6~~. (Previously presented) The nucleic acid of claim 1, wherein the transcriptional unit encodes the engineered JEV signal sequence and an M protein and an E protein of St. Louis encephalitis virus.

6 ~~7~~. (Previously presented) The nucleic acid of claim 1, wherein the transcriptional unit encodes the engineered JEV signal sequence and an M protein and an E protein of Powassan virus.

GW/TMH:gh 02/03/06 480776 1-001-01/0
PATENT

Attorney Reference Number 6395-64908-01
Application Number 09/826,115

7 ~~8~~. (Previously presented) The nucleic acid of claim 1, wherein the immunogenic flavivirus antigen is selected from the group consisting of an M protein of a flavivirus, an E protein of a flavivirus, both an M protein and an E protein of a flavivirus, a portion of an M protein of a flavivirus, a portion of an E protein of a flavivirus and both a portion of an M protein of a flavivirus and a portion of an E protein of a flavivirus or any combination thereof.

8 ~~9~~. (Previously presented) The nucleic acid of claim ~~8~~⁷, wherein the immunogenic flavivirus antigen is both the M protein and the E protein of a flavivirus.

9 ~~10~~. (Original) The nucleic acid of claim 1, wherein the nucleic acid is DNA.

10 ~~11~~. (Original) The nucleic acid of claim ~~10~~⁹, comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:15, SEQ ID NO:19, SEQ ID NO:21 and SEQ ID NO:23.

11 ~~12~~. (Previously presented) The nucleic acid of claim 1, wherein the transcriptional unit comprises a control sequence disposed appropriately such that it operably controls the synthesis of the immunogenic flavivirus antigen.

//
12 ~~13~~. (Original) The nucleic acid of claim ~~12~~, wherein the control sequence is the cytomegalovirus immediate early promoter.

13 ~~14~~. (Previously presented) The nucleic acid of claim 1, comprising a Kozak consensus sequence located at a translational start site for a polypeptide comprising the immunogenic flavivirus antigen encoded by the transcriptional unit.

14 ~~15~~. (Original) The nucleic acid of claim 1 wherein the transcriptional unit comprises a poly-A terminator.

15 ~~16~~. (Currently amended) An isolated cell comprising the nucleic acid of claim 1.

GW/TMH:gtb 02/03/06 480776 1-001-01/0
PATENT

Attorney Reference Number 6395-64908-01
Application Number 09/826,115

16 ~~17~~. (Original) A composition comprising the nucleic acid of claim 1 and a pharmaceutically acceptable carrier.

18 - 27. CANCELLED.

17 ~~28~~. (Previously presented) The nucleic acid of claim 1, wherein the immunogenic flavivirus antigen is a St. Louis encephalitis virus antigen.

29. CANCELLED.

30. CANCELLED.

31. CANCELLED.

18 ~~32~~. (Previously presented) The nucleic acid of claim 1, wherein the immunogenic flavivirus antigen is a yellow fever virus antigen.

33. CANCELLED.

19 ~~34~~. (Previously presented) The nucleic acid of claim 1, wherein the immunogenic flavivirus antigen is a dengue virus antigen.

35. CANCELLED.

20 ~~36~~. (Previously presented) The nucleic acid of claim 1, wherein the immunogenic flavivirus antigen is a West Nile virus antigen.

37 - 43. CANCELLED.